Orasis expands access to presbyopia treatment with Qlosi starter packs

Orasis Pharmaceuticals has introduced Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% Starter Packs, aiming to expand access to its presbyopia treatment and enhance hands-on experience for eye care professionals, according to a press release.

Each Starter Pack contains 10 single-use vials, which is enough for 5 days of twice-daily treatment, along with tools to track progress and facilitate follow-up discussions.

Qlosi remains the only FDA-approved eye drop formulated with the lowest effective concentration of pilocarpine, using the company’s proprietary EyeQ Formulation to enhance near vision while maintaining distance and night vision quality. Clinical trials demonstrated a favorable safety and tolerability profile.

Read the full press release here.